Work

Glp-1r/gipr Dual Agonism Reduces Intestinal Lipid Secretion

Year: 2026
Type: dissertation
Abstract: Atherogenic dyslipidemia is a major contributor to cardiovascular disease in obesity and type 2 diabetes mellitus and is partly driven by dysregulated intestinal lipoprotein secretion. Tirzepatide, a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, improves glycemic control and reduces body weight. Although clinical studies show improvements in circulating lipid profiles, whether tirzepatide modulates intestinal lipid secretion remains unclear. This study investigated the effects of GLP-1R/GIPR dual agonism with tirzepatide on intestinal lipid secretion in Sprague-Dawley rats. Rats were fed a high-fat diet (HFD) or a control diet (CD) for eight weeks. Intraperitoneal glucose tolerance tests (IPGTT) were performed at week 6. During the final week, rats received daily subcutaneous injection of tirzepatide (10 nmol/kg/day) or placebo. At the end of feeding, rats were surgically implanted with intraduodenal and mesenteric lymph duct catheters. Lipid was provided into the duodenum, and lymph was collected for 4 hours. Lymph triglyceride (TG) output and apolipoprotein B (ApoB) output were measured. Expression of lipid metabolism and other related genes in jejunal mucosa, liver, and adipose tissue was assessed by RT-qPCR. High-fat feeding increased energy intake and intestinal lipoprotein secretion. Tirzepatide treatment attenuated lymph TG and ApoB output in both dietary groups and altered the expression of genes involved in intestinal lipid uptake, synthesis, and lipoprotein assembly, while producing modest transcriptional changes in genes related to lipid metabolism in the liver and adipose tissue. Together, these findings indicate that GLP-1R/GIPR dual agonism with tirzepatide modulates intestinal lipid metabolism and reduces diet-induced intestinal lipoprotein overproduction. These intestinal effects may represent a mechanism that contributes to the cardiometabolic benefits associated with tirzepatide therapy and support the intestine as an important site of action for dual incretin receptor agonism.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7162722169
Cites: 124
Cited by:
Related to: 10